Welch Group LLC Increases Holdings in AbbVie Inc. $ABBV

Posted by Brian Himes on Aug 19th, 2026

Welch Group LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 371,366 shares of the company’s stock after purchasing an additional 5,433 shares during the period. AbbVie comprises about 3.2% of Welch Group LLC’s investment portfolio, making the stock its 3rd biggest position. Welch Group LLC’s holdings in AbbVie were worth $93,451,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Legacy Wealth Managment LLC ID increased its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie in the 4th quarter worth approximately $31,000. Finally, Abound Financial LLC bought a new stake in AbbVie during the 4th quarter worth approximately $32,000. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. Cantor Fitzgerald lifted their price target on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price on the stock in a research note on Thursday, August 13th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Finally, Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.73.

Get Our Latest Research Report on AbbVie

AbbVie Price Performance

ABBV stock opened at $259.01 on Wednesday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The business has a 50 day simple moving average of $246.17 and a two-hundred day simple moving average of $226.63. The company has a market capitalization of $457.63 billion, a price-to-earnings ratio of 73.17, a PEG ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is presently 195.48%.

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.